Imaging Groups Oppose CMS Coverage Proposal For Beta-Amyloid PET

Medical imaging manufacturers and professional societies echoed Eli Lilly’s criticism of the CMS proposal to cover beta-amyloid PET for use in patients suffering from dementia and neurodegenerative disease.